Figure 2.
Figure 2. Overall survival and time to progression. Overall survival (top curve) and time to progression to accelerate or blastic phase accelerated or blastic phase (bottom curve) according to the degree of CgR, major (complete plus partial, solid line) versus minor or minimal or none (dotted line). With a median observation time of 26 months, survival is 97% for MCgRs versus 92% for the others (P = .122) and the cumulative rate of progression to accelerated or blastic phase is 4% for MCgRs versus 13% for the others (P = .037; log-rank test, Kaplan-Meier estimates).28,29 The analysis was not corrected for the time to response, because almost all MCgRs were achieved during the first 3 months, and in this period there were no events.

Overall survival and time to progression. Overall survival (top curve) and time to progression to accelerate or blastic phase accelerated or blastic phase (bottom curve) according to the degree of CgR, major (complete plus partial, solid line) versus minor or minimal or none (dotted line). With a median observation time of 26 months, survival is 97% for MCgRs versus 92% for the others (P = .122) and the cumulative rate of progression to accelerated or blastic phase is 4% for MCgRs versus 13% for the others (P = .037; log-rank test, Kaplan-Meier estimates).28,29  The analysis was not corrected for the time to response, because almost all MCgRs were achieved during the first 3 months, and in this period there were no events.

Close Modal

or Create an Account

Close Modal
Close Modal